Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | ASXL1 wild-type TET2 mut |
Therapy | Azacitidine |
Indication/Tumor Type | myelodysplastic/myeloproliferative neoplasm |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ASXL1 wild-type TET2 mut | myelodysplastic/myeloproliferative neoplasm | sensitive | Azacitidine | Clinical Study - Cohort | Actionable | In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413). | 25224413 |
PubMed Id | Reference Title | Details |
---|---|---|
(25224413) | TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. | Full reference... |